HYNR-CS-Allo is under clinical development by Corestemchemon and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect HYNR-CS-Allo’s likelihood of approval (LoA) and phase transition for Cerebellar Ataxia took place on 28 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 28 May 2021 decreased HYNR-CS-Allo’s Phase Transition Success Rate (PTSR) for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), and decreased PTSR for Spinocerebellar Ataxia (SCA).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HYNR-CS-Allo Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

HYNR-CS-Allo overview

HYNR-CS-Allo (HLA-haplo matched allogenic bone marrow derived stem cells) is under development for the treatment of cerebellar ataxia, multiple system atrophyspinocerebellar ataxia and amyotrophic lateral sclerosis (ALS). It administered intrathecally as suspension. This therapy comprises of allogenic bone marrow derived mesenchymal stem cells.

Corestemchemon overview

Corestemchemon, formerly Corestem, is a biotechnology company that researches and commercializes stem cell technology. It develops stem cell therapy for the treatment of incurable diseases. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of Lou Gehrig’s disease. The company’s other pipeline products include CS20AT04 (Lupus), CS10BR05 (MSA), which are at the stage of phase I clinical trial. Corestemchemon is involved in research and development activities in the fields of stem cell therapy. The company also develops various therapy products for the treatment of lupus, multiple system atrophy, osteoarthritis, and other diseases. Corestemchemon is headquartered in Seongnam-si, Gyeonggi-do, South Korea.

Quick View HYNR-CS-Allo LOA Data

Report Segments
  • Innovator
Drug Name
  • HYNR-CS-Allo
Administration Pathway
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.